- Conditions
- Solid Tumor
- Interventions
- Eribulin ORA
- Combination Product
- Lead sponsor
- Health Hope Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Buffalo, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2401–2424
of 11,392
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Relapsed Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Richter Syndrome, MYC Amplification, MYC Overexpression, MYC Translocation
- Interventions
- VIP152, BTKi
- Drug
- Lead sponsor
- Vincerx Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 4
- States / cities
- Cincinnati, Ohio • Columbus, Ohio • Dallas, Texas + 1 more
- Conditions
- Multiple Sclerosis
- Interventions
- Not listed
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,604 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Pancreatic Acinar Cell Carcinoma
- Interventions
- Olaparib, ECG, CT CAP, Tumor Biopsy
- Drug · Diagnostic Test · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Healthy
- Interventions
- Probe Drug Cocktail, Lasmiditan, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Daytona Beach, Florida
- Conditions
- Melanoma (Skin)
- Interventions
- therapeutic autologous lymphocytes, Use of an artificial antigen presenting cell (aAPC) to generate CTL, GM-CSF, Irradiation of cutaneous tumor lesion
- Biological · Genetic · Drug + 1 more
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Agitation,Psychomotor, Dementia
- Interventions
- Sublingual film containing Dexmedetomidine, Sublingual Placebo Film
- Drug
- Lead sponsor
- BioXcel Therapeutics Inc
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 5
- States / cities
- Homestead, Florida • Miami Lakes, Florida • Springfield, Massachusetts + 2 more
- Conditions
- Advanced Malignant Solid Neoplasm, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
- Interventions
- Support Group Therapy, Symptom Management Service (SMS) Consultation, Quality of Life (QOL) Questionnaires, Interview
- Behavioral · Other
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- B-cell Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, B-cell Lymphoma
- Interventions
- IKS03
- Drug
- Lead sponsor
- Iksuda Therapeutics Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- E.Coli Infections, Bloodstream Infection
- Interventions
- SNIPR001, Placebo
- Drug
- Lead sponsor
- SNIPR Biome Aps.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Multiple Myeloma
- Interventions
- STI-1492
- Biological
- Lead sponsor
- Sorrento Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 3
- States / cities
- Orange, California • Sacramento, California • Oklahoma City, Oklahoma
- Conditions
- Colorectal Cancer
- Interventions
- xBar™ System
- Device
- Lead sponsor
- Exero Medical Ltd.
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 6
- States / cities
- Louisville, Kentucky • Baltimore, Maryland • Lincoln, Nebraska + 2 more
- Conditions
- Genito-Urinary Neoplasm
- Interventions
- Biospecimen Collection(Punch Biopsy)
- Procedure
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Cancer
- Interventions
- Ixabepilone, 5 mg/d, Ixabepilone, 10 mg/d, Ixabepilone, 15 mg/d, Ixabepilone, 20 mg/d, Ixabepilone, 25 mg/d, Ixabepilone, 30 mg/d, Ixabepilone, 25 mg, with famotidine, Ixabepilone, 25 mg, with food
- Drug
- Lead sponsor
- R-Pharm
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia • Detroit, Michigan
- Conditions
- Cystic Fibrosis
- Interventions
- Not listed
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 6 Months and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Cancer
- Interventions
- Multi-Cancer Early Detection Test
- Device
- Lead sponsor
- GRAIL, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 6,662 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2022
- U.S. locations
- 11
- States / cities
- Roseville, California • Pensacola, Florida • Boston, Massachusetts + 8 more
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Sacituzumab Govitecan-hziy (SG), Pembrolizumab, Carboplatin, Cisplatin
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 193 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 22
- States / cities
- Anchorage, Alaska • Beverly Hills, California • Los Angeles, California + 17 more
- Conditions
- Candida Infection, Oral Thrush, Early Childhood Caries
- Interventions
- Not listed
- Lead sponsor
- Temple University
- Other
- Eligibility
- 9 Months to 15 Months
- Enrollment
- 70 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Cancer, Relapsed/Refractory Large B-cell Lymphoma (LBCL)
- Interventions
- Fludarabine (Conditional therapy), Cyclophosphamide Monohydrate (Conditional therapy), firi-cel (Experimental drug)
- Drug
- Lead sponsor
- CARGO Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 31
- States / cities
- Little Rock, Arkansas • Duarte, California • Los Angeles, California + 24 more
- Conditions
- Healthy Volunteers
- Interventions
- Propranolol, Pindolol, Dantrolene, Magnesium Sulfate, Caffeine, Qsymia, Topiramate, Phentermine, Naltrexone, Mirabegron 50mg, Mirabegron 200mg, Placebo Cohort 1, Placebo Cohort 2, Placebo for Mirabegron
- Drug · Behavioral
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 18 Years to 35 Years · Male only
- Enrollment
- 47 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2024
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Cardiovascular Disease
- Interventions
- GSK2212836
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Leukemia
- Interventions
- arsenic trioxide
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- Not listed
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2002
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Metastatic Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma
- Interventions
- 5-Fluorouracil, Oxaliplatin, Leucovorin, Irinotecan, Gemcitabine, Nab Paclitaxel, Circulating Tumor Deoxyribonucleic acid (ctDNA) Assay
- Drug · Diagnostic Test
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Pregnancy Related, Pregnancy Complications, Pregnancy, High Risk
- Interventions
- Relugolix-Containing Product
- Drug
- Lead sponsor
- Sumitomo Pharma Switzerland GmbH
- Industry
- Eligibility
- 0 Years and older · Female only
- Enrollment
- 728 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2033
- U.S. locations
- 1
- States / cities
- Wilmington, North Carolina